Wellington Management Group LLP Sells 32,946 Shares of IQVIA Holdings Inc. $IQV

Wellington Management Group LLP decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 45.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,928 shares of the medical research company’s stock after selling 32,946 shares during the period. Wellington Management Group LLP’s holdings in IQVIA were worth $7,715,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC raised its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of IQVIA during the second quarter worth about $514,000. First Trust Advisors LP increased its position in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 3.1%

Shares of IQV stock opened at $259.49 on Wednesday. The business has a 50-day moving average of $233.34 and a 200 day moving average of $194.19. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $271.80. The stock has a market capitalization of $42.71 billion, a PE ratio of 32.19, a P/E/G ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In related news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock worth $3,796,021 over the last ninety days. 1.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IQV shares. Mizuho lifted their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Royal Bank Of Canada raised their price objective on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $243.62.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.